1.35
Schlusskurs vom Vortag:
$1.37
Offen:
$1.35
24-Stunden-Volumen:
2.67M
Relative Volume:
1.62
Marktkapitalisierung:
$82.88M
Einnahmen:
$5.03M
Nettoeinkommen (Verlust:
$-185.41M
KGV:
-0.4369
EPS:
-3.09
Netto-Cashflow:
$-139.79M
1W Leistung:
+4.65%
1M Leistung:
-8.78%
6M Leistung:
-90.22%
1J Leistung:
-88.91%
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Firmenname
Pliant Therapeutics Inc
Sektor
Branche
Telefon
650-481-6770
Adresse
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Vergleichen Sie PLRX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
PLRX
Pliant Therapeutics Inc
|
1.35 | 79.19M | 5.03M | -185.41M | -139.79M | -3.09 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-04 | Fortgesetzt | Cantor Fitzgerald | Neutral |
2025-03-04 | Herabstufung | Needham | Buy → Hold |
2025-03-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
2025-03-03 | Herabstufung | Stifel | Buy → Hold |
2025-02-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
2025-02-10 | Herabstufung | Citigroup | Buy → Neutral |
2025-02-10 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2025-02-10 | Herabstufung | JP Morgan | Overweight → Neutral |
2025-02-10 | Herabstufung | Oppenheimer | Outperform → Perform |
2025-02-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2025-02-10 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
2023-05-18 | Eingeleitet | Canaccord Genuity | Buy |
2023-04-13 | Eingeleitet | Robert W. Baird | Outperform |
2022-12-14 | Eingeleitet | Stifel | Buy |
2022-12-07 | Eingeleitet | JP Morgan | Overweight |
2022-09-01 | Eingeleitet | Citigroup | Buy |
2022-07-20 | Eingeleitet | SVB Leerink | Outperform |
2022-05-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
2021-11-24 | Eingeleitet | RBC Capital Mkts | Outperform |
2021-11-03 | Eingeleitet | H.C. Wainwright | Buy |
2021-04-20 | Eingeleitet | BTIG Research | Buy |
2021-04-05 | Eingeleitet | Citigroup | Buy |
2020-06-29 | Eingeleitet | Citigroup | Buy |
2020-06-29 | Eingeleitet | Cowen | Outperform |
2020-06-29 | Eingeleitet | Needham | Buy |
2020-06-29 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Pliant Therapeutics Inc Aktie (PLRX) Neueste Nachrichten
Pliant Therapeutics presents new fibrosis treatment data By Investing.com - Investing.com Canada
Pliant Therapeutics Presents Clinical and Preclinical Data at th - GuruFocus
Pliant Therapeutics presents new fibrosis treatment data - Investing.com
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference | PLRX Stock News - GuruFocus
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society ... - Eagle-Tribune
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference - GlobeNewswire
Breakthrough: Pliant's New Lung Disease Drug Outperforms Standard Treatment in Latest Clinical Data - Stock Titan
How Are Things Looking For Pliant Therapeutics Inc (NASDAQ: PLRX) For The Short Term? - Stocksregister
Cautious Hold Rating on Pliant Therapeutics Amid Clinical and Financial Uncertainties - TipRanks
Another Bay Area biotech company announces layoffs - MSN
Pliant Therapeutics Reports Q1 2025 Financial Results - TipRanks
Pliant (PLRX) Prepares to Release Topline Results from BEACON-IP - GuruFocus
Pliant (PLRX) Prepares to Release Topline Results from BEACON-IPF Trial | PLRX Stock News - GuruFocus
Pliant Therapeutics reports Q1 EPS (92c), consensus (62c) - TipRanks
Pliant Therapeutics (PLRX) Advances in Clinical Trials and Oncology Research | PLRX Stock News - GuruFocus
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - GlobeNewswire
Market Watch Highlights: Pliant Therapeutics Inc (PLRX) Ends on an Downturn Note at 1.43 - DWinneX
Pliant Therapeutics Cuts Workforce by Nearly Half - Powder & Bulk Solids
Bay Area biotech company Pliant Therapeutics slashes staff after losing $655 million in value - MSN
Pliant cuts workforce by 45% following lung trial termination - Clinical Trials Arena
Pliant Therapeutics to cut 45% of workforce (PLRX:NASDAQ) - Seeking Alpha
Pliant Therapeutics (PLRX) Restructures to Prolong Financial Res - GuruFocus
Pliant Therapeutics Reduces Workforce as Part of Strategic Realignment - MarketWatch
Pliant Therapeutics (PLRX) Restructures to Prolong Financial Resources | PLRX Stock News - GuruFocus
Pliant Therapeutics announces workforce reduction By Investing.com - Investing.com India
Pliant Therapeutics announces workforce reduction - Investing.com
Pliant Therapeutics Announces Major Workforce Reduction - TipRanks
Pliant Therapeutics Announces Workforce Reduction and Cost Saving Initiatives to Support Late-Stage Clinical Trials - Nasdaq
Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations - GlobeNewswire
Pliant Therapeutics Slashes Nearly Half its Workforce While Awaiting Crucial IPF Drug Results - Stock Titan
You might want to take a look at Pliant Therapeutics Inc (PLRX) now - Sete News
Pliant Therapeutics Inc [PLRX] stock was sold by Coulie Bernard at the price of US$0.59 million - knoxdaily.com
Market Momentum: Pliant Therapeutics Inc (PLRX) Registers a 0.68 Increase, Closing at 1.48 - DWinneX
Stock Performance Spotlight: Cg Oncology Inc (CGON) Ends the Day at 26.94, Down by -3.68 - DWinneX
Pliant Therapeutics Inc (PLRX)’s highs and lows: A closer look at its stock price fluctuations - uspostnews.com
Legal & General Group Plc Grows Stock Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
Pliant Therapeutics Inc: A Year of Highs, Lows, and Market Resilience - investchronicle.com
Press Release Distribution & PR Platform - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc.PLRX - Louisiana First News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant ... - Bluefield Daily Telegraph
Pliant Therapeutics discovers new integrin αvβ1, αvβ6 and/or αvβ8 antagonists - BioWorld MedTech
Pliant Therapeutics Inc’s Market Journey: Closing Weak at 3.03, Down -1.62 - DWinneX
PLRXPliant Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Healthy Upside Potential: Pliant Therapeutics Inc (PLRX) - Sete News
Market Recap Check: Pliant Therapeutics Inc (PLRX)’s Positive Finish at 1.54, Up/Down 2.67 - DWinneX
Pliant Therapeutics Inc (PLRX)’s stock price in review: A technical analysis - uspostnews.com
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Bought by JPMorgan Chase & Co. - Defense World
Finanzdaten der Pliant Therapeutics Inc-Aktie (PLRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):